CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
Authors
Keywords
-
Journal
Current Pain and Headache Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-14
DOI
10.1007/s11916-022-01056-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hypertension: A new safety risk for patients treated with erenumab
- (2021) Suprat Saely et al. HEADACHE
- Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
- (2021) J. Talbot et al. JOURNAL OF HEADACHE AND PAIN
- Early outcomes of migraine after erenumab discontinuation: data from a real-life setting
- (2021) Eleonora De Matteis et al. NEUROLOGICAL SCIENCES
- Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study
- (2021) Andreas R Gantenbein et al. CEPHALALGIA
- Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP monoclonal antibodies preventive treatment: A real‐world evidence study
- (2021) Alicia Alpuente et al. EUROPEAN JOURNAL OF NEUROLOGY
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
- (2021) Andrew M. Blumenfeld et al. Pain and Therapy
- Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
- (2021) Simone de Vries Lentsch et al. EUROPEAN JOURNAL OF NEUROLOGY
- Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
- (2021) Bianca Raffaelli et al. CEPHALALGIA
- Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
- (2021) David W. Dodick et al. HEADACHE
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
- (2021) Sara Bottiroli et al. JOURNAL OF HEADACHE AND PAIN
- CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
- (2021) Fenne Vandervorst et al. JOURNAL OF HEADACHE AND PAIN
- Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials
- (2021) Chun-Pai Yang et al. Neurotherapeutics
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
- (2020) Lanfranco Pellesi et al. HEADACHE
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine
- (2020) Chun-Pai Yang et al. CURRENT MEDICAL RESEARCH AND OPINION
- Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study
- (2020) Ashley Alex et al. HEADACHE
- No ‘Wearing‐off Effect’ Seen in Quarterly or Monthly Dosing of Fremanezumab: Sub‐analysis of a Randomized Long‐term Study
- (2020) Andrew M. Blumenfeld et al. HEADACHE
- The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
- (2020) Stephen D. Silberstein et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Erenumab efficacy in highly resistant chronic migraine: a real-life study
- (2020) Umberto Pensato et al. NEUROLOGICAL SCIENCES
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2
- (2020) Hans‐Christoph Diener et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in chronic migraine
- (2019) Richard B. Lipton et al. NEUROLOGY
- Erenumab in chronic migraine with medication overuse
- (2019) Stewart J. Tepper et al. NEUROLOGY
- Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
- (2019) David W Dodick et al. CEPHALALGIA
- Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
- (2019) Bianca Raffaelli et al. JOURNAL OF HEADACHE AND PAIN
- Current and emerging evidence-based treatment options in chronic migraine: a narrative review
- (2019) Elio Clemente Agostoni et al. JOURNAL OF HEADACHE AND PAIN
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
- (2019) Messoud Ashina et al. CEPHALALGIA
- Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2019) Paul K. Winner et al. HEADACHE
- Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies
- (2019) J. Ailani et al. EUROPEAN JOURNAL OF NEUROLOGY
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine
- (2018) Todd Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic migraine: risk factors, mechanisms and treatment
- (2016) Arne May et al. Nature Reviews Neurology
- Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine
- (2015) Tony W Ho et al. CEPHALALGIA
- Treatment of medication-overuse headache: A systematic review
- (2015) Chia-Chun Chiang et al. CEPHALALGIA
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
- (2014) T. W. Ho et al. NEUROLOGY
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline
- (2013) Stephen D. Silberstein et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Chronic migraine and chronic daily headache in the Asia-Pacific region: A systematic review
- (2012) Richard J Stark et al. CEPHALALGIA
- Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study
- (2012) Dawn C. Buse et al. HEADACHE
- Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study
- (2011) Dawn Buse et al. HEADACHE
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- (2010) SK Aurora et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- (2010) HC Diener et al. CEPHALALGIA
- Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
- (2010) Min Yang et al. CEPHALALGIA
- Comorbidity of Depressive and Anxiety Disorders in Chronic Daily Headache and Its Subtypes
- (2010) Kai-Dih Juang et al. HEADACHE
- Utility of Topiramate for the Treatment of Patients with Chronic Migraine in the Presence or Absence of Acute Medication Overuse
- (2009) H-C Diener et al. CEPHALALGIA
- Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population-Based Study
- (2008) Marcelo E. Bigal et al. HEADACHE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started